Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 30, Issue 3, 2009, Pages 364-376

  Wang, Yan Jiang ^a,b   Pollard, Anthony ^a   Zhong, Jin Hua ^a   Dong, Xiao Yan ^c   Wu, Xiao Bing ^c   Zhou, Hua Dong ^b   Zhou, Xin Fu ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Center for Disease Control   (China)

Author keywords

Adeno associated virus; Alzheimer's disease; Amyloid beta; Immunotherapy; Intramuscular delivery; Single chain antibody

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CELL ACTIVATION; CELL SEPARATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FIBER; GENE; GENE DELIVERY SYSTEM; HIPPOCAMPUS; IMMUNOTHERAPY; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENILE PLAQUE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY GENE; SYSTEMATIC REVIEW; T LYMPHOCYTE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, TRANSGENIC; SINGLE-CHAIN ANTIBODIES;

EID: 58549116371     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.06.013     Document Type: Article

References (42)

1. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., and Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad Sci. U.S.A. 100 4 (2003) 2023-2028
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 8 (2000) 916-919
3. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 5 (2005) 675-688
4. Brantly M.L., Spencer L.T., Humphries M., Conlon T.J., Spencer C.T., Poirier A., Garlington W., Baker D., Song S., Berns K.I., Muzyczka N., Snyder R.O., Byrne B.J., and Flotte T.R. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17 12 (2006) 1177-1186
5. Brendza R.P., Bacskai B.J., Cirrito J.R., Simmons K.A., Skoch J.M., Klunk W.E., Mathis C.A., Bales K.R., Paul S.M., Hyman B.T., and Holtzman D.M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115 2 (2005) 428-433
6. Cai J., Wang S., Zhong Y., Cheng J., Ji Z., Sheng S., and Zhang C. Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40. Neuroreport 14 2 (2003) 265-268
7. Carty N.C., Wilcock D.M., Rosenthal A., Grimm J., Pons J., Ronan V., Gottschall P.E., Gordon M.N., and Morgan D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J. Neuroinflamm. 3 (2006) 11
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98 15 (2001) 8850-8855
9. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., and Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295 5563 (2002) 2264-2267
10. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 5 (2002) 452-457
11. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 1 (2004) 11-20
12. Flotte T.R. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 11 10 (2004) 805-810
13. Fukuchi K., Tahara K., Kim H.D., Maxwell J.A., Lewis T.L., Accavitti-Loper M.A., Kim H., Ponnazhagan S., and Lalonde R. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 23 2 (2006) 502-511
14. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., and Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 9 (2005) 1553-1562
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 5580 (2002) 353-356
16. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 4 (2003) 547-554
17. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 9 (2005) 1126-1136
18. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., and Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17 6 (2001) 157-165
19. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 6815 (2000) 979-982
20. Jiang H., Pierce G.F., Ozelo M.C., de Paula E.V., Vargas J.A., Smith P., Sommer J., Luk A., Manno C.S., High K.A., and Arruda V.R. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 14 3 (2006) 452-455
21. LeVine III H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 3 (1993) 404-410
22. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., and Golde T.E. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116 1 (2006) 193-201
23. Levites Y., Jansen K., Smithson L.A., Dakin R., Holloway V.M., Das P., and Golde T.E. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. 26 46 (2006) 11923-11928
24. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., and Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43 22 (2004) 6959-6967
25. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., and Lemere C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26 18 (2006) 4717-4728
26. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., and Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 1 (2005) 129-131
27. Mori S., Takeuchi T., Enomoto Y., Kondo K., Sato K., Ono F., Iwata N., Sata T., and Kanda T. Biodistribution of a low dose of intravenously administered AAV-2, 10 and 11 vectors to cynomolgus monkeys. Jpn. J. Infect. Dis. 59 5 (2006) 285-293
28. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 4 (2003) 448-452
29. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 5597 (2002) 1379
30. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., and DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25 3 (2005) 629-636
31. Rogers J., and Shen Y. A perspective on inflammation in Alzheimer's disease. Ann. N.Y. Acad. Sci. 924 (2000) 132-135
32. Rohn T.T., Ivins K.J., Bahr B.A., Cotman C.W., and Cribbs D.H. A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis. J. Neurochem. 74 6 (2000) 2331-2342
33. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 6740 (1999) 173-177
34. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 94 8 (1997) 4109-4112
35. Solomon B., Koppel R., Hanan E., and Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. U.S.A. 93 1 (1996) 452-455
36. Tamura Y., Hamajima K., Matsui K., Yanoma S., Narita M., Tajima N., Xin K.Q., Klinman D., and Okuda K. The F(ab)′2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis. 20 2 (2005) 541-549
37. Wang Y.J., Zhou H.D., and Zhou X.F. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov. Today 11 19/20 (2006) 931-938
38. Wilcock D.M., Alamed J., Gottschall P.E., Grimm J., Rosenthal A., Pons J., Ronan V., Symmonds K., Gordon M.N., and Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 26 20 (2006) 5340-5346
39. Wilcock D.M., Munireddy S.K., Rosenthal A., Ugen K.E., Gordon M.N., and Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15 1 (2004) 11-20
40. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., and Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflamm. 1 1 (2004) 24
41. Yan H., Guo Y., Zhang P., Zu L., Dong X., Chen L., Tian J., Fan X., Wang N., Wu X., and Gao W. Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. Biochem. Biophys. Res. Commun. 336 1 (2005) 287-298
42. Zhang J., Wu X., Qin C., Qi J., Ma S., Zhang H., Kong Q., Chen D., Ba D., and He W. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 14 3 (2003) 365-379